Pharmachain AI

08/18/2026

08/18/2026

Peptides, short chains of amino acids, have surged in popularity online, promoted for benefits ranging from muscle growth to anti-aging. While some peptide-based drugs like insulin and GLP-1 medications (Ozempic, Wegovy) are FDA-approved, many products circulating on social media are experimental and labeled “for research use only.”

In Collierville, Tennessee, pharmacist Dr. Ryan Wooden demonstrates how a 3D printer produces testosterone lozenges at his compounding pharmacy. Soon, patients may also be able to purchase peptides directly from such pharmacies. Peptides—short chains of amino acids—have surged in popularity onli...

08/17/2026

It’s a brand new week; let’s put health first! 💙 Stay hydrated, eat fresh, and keep moving. Pharmachain makes wellness simple and accessible for everyone.

08/13/2026

After an all-nighter with patients, my eyes and I are no longer on speaking terms.

08/12/2026

Cleveland Clinic has become the first U.S. hospital to deploy a long-term drone delivery program for prescription medications. This innovative step is aimed at improving patient access to essential drugs, especially for those who face mobility challenges or live in areas where traditional delivery s...

08/11/2026

No more searching in circles, Pharmachain AI brings medicine to your fingertips.

゚viralシ

08/10/2026

It’s a new week, a fresh chance to begin again, to grow, and to make progress that matters.
゚viralシ

08/07/2026

Finding your medicine shouldn’t add to the headache. PharmaChain AI makes it simple, fast, and stress‑free.

゚viralシ

08/05/2026

In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) shocked many observers by narrowly recommending six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for potential inclusion on the 503A Bulks List.

In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) shocked many observers by narrowly recommending six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for potential inclusion on the 503A Bulks List. This decision went against FDA scientists, who had advised ...

08/05/2026

As more employers stop covering GLP‑1 weight‑loss drugs like Wegovy and Zepbound, Americans are turning to direct‑to‑consumer (DTC) prescription programs. Big retailers, Walmart, Costco, CVS, and Amazon, are seizing this opportunity to expand their share of the pharmacy market
Read more:

As more employers stop covering GLP‑1 weight‑loss drugs like Wegovy and Zepbound, Americans are turning to direct‑to‑consumer (DTC) prescription programs. Big retailers, Walmart, Costco, CVS, and Amazon, are seizing this opportunity to expand their share of the pharmacy market. These prescri...